Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available "by early ...

Canadian drug developer Medicago's plant-based COVID-19 vaccine candidate, enhanced by GlaxoSmithKline's booster, was 75.3% effective against the Delta variant of the virus in a late stage study ...

Medicago said it would file the adjuvanted plant-based coronavirus vaccine for regulatory approval with Health Canada, the FDA and others.

Pharmaceutical companies GlaxoSmithKline and Medicago announced positive results from phase three trials for the first plant-based vaccine against covid-19 on Tuesday. The two drugmakers have ...

Medicago’s Covifenz is the only authorized COVID-19 vaccine that is plant-based. To make the vaccine, the company uses nicotiana benthamiana, a cousin of the tobacco plant, as small bioreactors ...

Medicago – a Canadian company with a biomanufacturing facility in Durham – has used it to produce an experimental plant-based vaccine for COVID-19, the coronavirus disease that has now reached ...

Medicago needs about 30 days to develop vaccine from leaves of the plant, which makes it faster than traditional vaccine-development methods that use chicken eggs to incubate the virus.

Canada's Medicago, a biotech that is using plant technology to manufacture vaccines against Ebola and other viruses, will build a $200 million manufacturing facility in Quebec City. The company is ...

Pharmaceutical companies Medicago and GlaxoSmithKline announced Tuesday “positive efficacy and safety results” from a global trial using what they say is the world’s first plant-based ...

Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory revi ...

Medicago is based in Canada but has a big operation in RTP. The companies are developing a COVID-19 vaccine that combines the latter’s Coronavirus Virus-Like Particles with GSK’s adjuvant.

VLP vaccine will be produced using plant leaf production system. Canadian vaccines firm Medicago has been awarded $946,000 in funding from PATH as part of a research collaboration between the ...